---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-083634"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:48:48.139354+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Adial shareholders approve equity plan amendment increasing authorized shares to 500,000; re-elect directors

## Summary
- Stockholders approved Amendment No. 5 to 2017 Equity Incentive Plan, increasing shares from 380,000 to 500,000.
- Cary J. Claiborne and Robertson H. Gilliland re-elected as Class II directors for three-year terms.
- Marcum LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2023.

## SEC filing metadata
- accession: 0001213900-23-083634
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390023083634/0001213900-23-083634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390023083634/ea187742-8k_adialpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-083634
- JSON: https://secwatch.observer/filing/0001213900-23-083634.json
- Plain text: https://secwatch.observer/filing/0001213900-23-083634.txt

## Key facts
- Shareholder Votes
  ADIAL PHARMACEUTICALS, INC. shareholders approved Approval of an amendment to the Company’s 2017 Equity Incentive Plan to increase the number of shares of common stock authorized for grant under the plan from 380,000 to 500,000 at the 2023-11-02 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-11-02
  source text: The stockholders approved the amendment (Amendment No. 5) to the Company’s 2017 Equity Incentive Plan to increase the number of shares of common stock authorized for grant under the 2017 Equity Incentive Plan from 380,000 to 500,000 based on the votes listed below: Votes For Votes Against Abstentions Broker Non-Votes 244,858 113,670 1,097 197,676
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390023083634/0001213900-23-083634-index.htm
- Shareholder Votes
  ADIAL PHARMACEUTICALS, INC. shareholders approved Election of Directors at the 2023-11-02 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-11-02
  source text: On November 2, 2023, at the Annual Meeting, the Company’s stockholders voted on the following three (3) proposals and votes were cast as described below.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390023083634/0001213900-23-083634-index.htm
- Shareholder Votes
  ADIAL PHARMACEUTICALS, INC. shareholders approved Ratification of the appointment of Marcum, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-11-02 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-11-02
  source text: The stockholders ratified and approved the appointment of Marcum, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, based on the votes listed below: Votes For Votes Against Abstentions 542,258 3,868 11,175
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390023083634/0001213900-23-083634-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.